Lidia Moreira Lima

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Instituto de Ciências Biomédicas

Departamento:

Docentes/ICB

ORCID:

https://orcid.org/0000-0002-8625-6351


Formação:

  • Universidad de Navarra

    | Pós-Doutorado | 2004 - 2005

  • Universidade Federal do Rio de Janeiro

    Química | Doutorado | 1997 - 2001

  • Universidade Federal do Rio de Janeiro

    Química | Mestrado | 1995 - 1997

  • Universidade Federal do Rio de Janeiro

    Farmácia | Graduação | 1991 - 1994
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:

(81.10% artigos com DOI)

Titulo DOI Ano
Stereochemical insights into β-amino- N -acylhydrazones and their impact on DPP-4 inhibition 10.1039/d4ra00450g 2024
Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile 10.3390/ph17030389 2024
In vitro results with minimal blood toxicity of a combretastatin A4 analogue 10.1007/s10637-024-01440-4 2024
Revisiting Nitroaromatic Drugs: Mechanisms of Bioactivation, Metabolism and Toxicity and Methods to Synthesize Nitroaromatic Fragments 10.21577/0103-5053.20240071 2024
Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib Analogues 10.3390/ph16020209 2023
Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent 10.3390/pharmaceutics15041282 2023
New phosphodiesterase-4 inhibitors present airways relaxant activity in a guinea pig acute asthma model 10.1007/s00210-023-02905-8 2023
Comparative chemical and biological hydrolytic stability of homologous esters and isosteres 10.1080/14756366.2022.2027933 2022
Design, synthesis, and biological evaluation of new thalidomide-donepezil hybrids as neuroprotective agents targeting cholinesterases and neuroinflammation 10.1039/d1md00374g 2022
Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs 10.3390/ph15080913 2022
Methyl Effect on the Metabolism, Chemical Stability, and Permeability Profile of Bioactive N -Sulfonylhydrazones 10.1021/acsomega.2c04368 2022
2-Arylpropionic Acid Pyrazolamides as Cannabinoid CB2 Receptor Inverse Agonists Endowed with Anti-Inflammatory Properties 10.3390/ph15121519 2022
Pre-clinical evaluation of LASSBio-1491: From in vitro pharmacokinetic study to in vivo leishmanicidal activity 10.1371/journal.pone.0269447 2022
Design and Synthesis In Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514 10.3390/molecules26164828 2021
LASSBio-596: a New Pre-clinical Candidate for Rheumatoid Arthritis? 10.1007/s10753-021-01564-2 2021
Carbamoyl- N -aryl-imine-urea: a new framework to obtain a putative leishmanicidal drug-candidate 10.1039/d0ra00287a 2020
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies 10.1016/j.ejmech.2020.112492 2020
β-lactam antibiotics: An overview from a medicinal chemistry perspective 10.1016/j.ejmech.2020.112829 2020

New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis

 10.2147/dddt.s258459 2020
COVID-19: Physiopathology and Targets for Therapeutic Intervention 10.21577/1984-6835.20200115 2020
A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives 10.1038/s41598-018-36846-7 2019
Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis 10.1016/j.exppara.2019.04.003 2019
Homologation: A versatile molecular modification strategy to drug discovery 10.2174/1568026619666190808145235 2019
Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats 10.1016/j.pharep.2019.07.005 2019
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling 10.1039/c9md00358d 2019
LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice 10.1016/j.ejphar.2019.172662 2019
Lung and liver responses to 1- and 7-day treatments with LASSBio-596 in mice subchronically intoxicated by microcystin-LR 10.1016/j.toxicon.2017.10.029 2018
Synthesis, Aqueous Solubility, Metabolic Stability and Pharmacological Profile of Simplified Urea Derivatives 10.2174/1570180814666171012155204 2018
Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones 10.1590/0001-3765201820170796 2018
N-Acylhydrazones as drugs 10.1016/j.bmcl.2018.07.015 2018
LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice 10.1371/journal.pone.0199009 2018
Oxidative imbalance in mice intoxicated by microcystin-LR can be minimized 10.1016/j.toxicon.2018.02.008 2018
Synthesis, Pharmacological Evaluation and Docking Study of a New Modulator of Microtubule Polymerization 10.2174/1570180814666171012162557 2018
Discovery of naphthyl- N -acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity 10.1111/cbdd.13085 2018
Natural products as new antimitotic compounds for anticancer drug development 10.6061/clinics/2018/e813s 2018
Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue 10.1016/j.molstruc.2017.06.093 2017
The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats 10.1111/jphp.12771 2017
A combined experimental and in silico characterization to highlight additional structural features and properties of a potentially new drug 10.1016/j.molstruc.2017.06.061 2017
Structural and physicochemical characterization of sulfonylhydrazone derivatives designed as hypoglycemic agents 10.1039/c7nj00074j 2017
Multi-gram Preparation of 7-Nitroquinoxalin-2-amine 10.21577/0103-5053.20170018 2017
Leishmanicidal candidate LASSBio-1736, a cysteine protease inhibitor with favorable pharmacokinetics: low clearance and good distribution 10.1080/00498254.2017.1405465 2017
Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome 10.1159/000443037 2016
Simple HPLC-UV for the quantification of a new leishmanicidal candidate ( E )-1-4(trifluoromethyl) benzylidene)-5-(2-4-dichlorozoyl) carbonylhydrazine (LASSBio-1736) in rat plasma for pharmacokinetics assessment 10.1002/bmc.3646 2016
Non-competitive Inhibitor of Nucleoside Hydrolase from Leishmania donovani Identified by Fragment-based Drug Discovery 10.1039/C6RA15143D 2016
Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents 10.2147/DDDT.S108327 2016
Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors 10.1371/journal.pone.0162895 2016
Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential Anti-Trypanosoma Cruzi Agents 10.2174/1573406412666160701022230 2016
Investigating the therapeutic effects of LASSBio-596 in an in vivo model of cylindrospermopsin-induced lung injury 10.1016/j.toxicon.2014.12.004 2015
Novel Orally Active Analgesic and Anti-Inflammatory Cyclohexyl-N-Acylhydrazone Derivatives 10.3390/molecules20023067 2015
Structural features evolution - from fluids to solid phase - and crystal morphology study of LASSBio 1601: a cyclohexyl-N-acylhydrazone derivative 10.1039/c5ra02696b 2015
Safrole and the Versatility of a Natural Biophore 10.5935/1984-6835.20150023 2015
Design, synthesis and in vitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives 10.1016/j.ejmech.2015.05.046 2015
Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema 10.3389/fphys.2015.00267 2015
Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors 10.1016/j.ejmech.2013.10.058 2014
Synchrotron X-ray powder diffraction data of LASSBio-1515: A new N-acylhydrazone derivative compound 10.1016/j.radphyschem.2013.02.014 2014
Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues 10.1371/journal.pone.0085380 2014
N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertensionthrough the modulation of adenosine AA2R activity 10.1016/j.ijcard.2014.02.022 2014
3-Aminothiophene-2-Acylhydrazones: Non-Toxic, Analgesic and Anti-Inflammatory Lead-Candidates 10.3390/molecules19068456 2014
In Vitro Microsomal Hepatic Metabolism of Antiasthmatic Prototype LASSBio-448 10.2174/1568026614666140506123718 2014
Novel Partial Agonist of PPAR-Gamma for Treatment of Diabetic Neuropathy in Rats 10.4172/2155-6156.1000392 2014
Toxicological in vitro and subchronic evaluation of LASSBio-596 10.1016/j.fct.2014.07.037 2014
Synthesis, Antiproliferative and Anti-inflammatory Activities of Novel Simplified Imatinib Analogues 10.4172/2161-0444.1000226 2014
Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates 10.1016/j.ejmech.2012.10.047 2013
New oxidovanadium(IV) N-acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents 10.1016/j.ejmech.2012.12.036 2013
Oral Antithrombotic Effects of Acylhydrazone Derivatives 10.5551/jat.14886 2013
Structure Re-determination of LASSBio-294 - a cardioactive compound of the N-acylhydrazone class - using X-ray powder diffraction data 10.1017/s0885715613000808 2013
Beirut Reaction and its Application in the Synthesis of Quinoxaline- -Dioxides Bioactive Compounds 10.5935/1984-6835.20130079 2013
Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives 10.1016/j.bmc.2012.01.034 2012
Synthesis, Biological Evaluation, and Structure-activity Relationship of Clonazepam, Meclonazepam, and 1,4-Benzodiazepine Compounds with Schistosomicidal Activity 10.1111/j.1747-0285.2012.01354.x 2012
Potential Inhibitory Effect of LASSBio-596, a New Thalidomide Hybrid, on Inflammatory Corneal Angiogenesis in Rabbits 10.1159/000337137 2012
LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis 10.2174/157340712801784778 2012
Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model 10.1016/j.ejphar.2012.05.043 2012
Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors 10.1016/j.ejmech.2012.05.006 2012
Design, Synthesis, Antinociceptive and Anti-Inflammatory Activities of Novel Piroxicam Analogues 10.3390/molecules171214126 2012
Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response 10.3390/molecules171214651 2012
Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists 10.2174/156802612804910205 2012
Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds to Treat Sickle Cell Disease Symptoms. Part II: Furoxan Derivatives 10.1021/jm300602n 2012
Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease 10.3390/molecules16042982 2011
LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR 10.1016/j.toxicon.2011.05.018 2011
Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds To Treat Sickle Cell Disease Symptoms 10.1021/jm200531f 2011
Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. 2011
Therapeutic approaches for tumor necrosis factor inhibition. Brazilian Journal of Pharmaceutical Sciences. 2011
A Arte de Criar o Artificial 2011
Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H2LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H2LASSBio-1064) and Their Zinc(II) Complexes 10.3390/molecules16086902 2011
Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H2LASSBio-1064) 10.1016/j.poly.2011.04.024 2011
Vasodilatory activity and antihypertensive profile mediated by inhibition of phosphodiesterase type 1 induced by a novel sulfonamide compound 10.1111/j.1472-8206.2011.00999.x 2011
Mutagenicity of New Lead Compounds to Treat Sickle Cell Disease Symptoms in a Salmonella/Microsome Assay 10.3390/ijms11020779 2010
Cardiovascular Effects of a Novel Synthetic Analogue of Naturally Occurring Piperamides 10.1097/FJC.0b013e3181ec061e 2010
Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR? 10.1016/j.toxicon.2010.06.005 2010
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates 10.1016/j.bmc.2010.06.002 2010
Cardiovascular effects induced by N-(4'-dihydro)-piperoylthiomorpholine in normotensive rats 10.1111/j.2042-7158.2010.01143.x 2010
LASSBio-596: da descoberta aos ensaios pré-clínicos. 2010
Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxide 10.1016/j.bmc.2008.10.086 2009
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates 10.1016/j.bmc.2008.11.065 2009
Synthesis, pharmacological evaluation and docking studies of new sulindac analogues 10.1016/j.ejmech.2008.11.012 2009
Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates 10.1016/j.ejmech.2009.02.026 2009
The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptors 10.1016/j.ejphar.2009.01.021 2009
LASSBio 's contribution in the development of novel antiasthmatic prototypes drug candidates 10.5935/1984-6835.20090006 2009
SYNTHESIS AND ANTI-PLATELET ACTIVITY OF NOVEL ARYLSULFONATE-ACYLHYDRAZONE DERIVATIVES, DESIGNED AS ANTITHROMBOTIC CANDIDATES 10.1016/j.ejmech.2007.03.032 2008
Antiplasmodial structure-activity relationship of 3-trifluoromethyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives 10.1016/j.exppara.2007.05.009 2008
Synthesis and structure-activity relationship of 3-phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents 10.1016/j.ejmech.2007.11.024 2008
. NSAIDs Revisited: Putative Molecular Basis of their Interactions with Peroxisome Proliferator-Activated gamma Receptor (PPAR-gamma) 10.1016/j.ejmech.2007.11.031 2008
Unexpected reduction of ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide derivatives with amines 10.3390/molecules13010078 2008
Química Medicinal Moderna: desafios e contribuição brasileira 10.1590/S0100-40422007000600015 2007
<a name="home"></a>Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma 10.1590/S0100-879X2006000200016 2006
Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates 10.2174/187152306775537328 2006
Antiplasmodial activity of 3-trifluoromethyl-2-carbonylquinoxaline di-N-oxide derivatives 10.1590/S1516-93322006000300005 2006
Microondas doméstico na síntese de derivados ftalimídicos 2006
Bioisosterism: an useful strategy for molecular modification 2005
LASSBio-468: a new achiral thalidomide analogue which modulates TNF-alfa and NO production and inhibits endotoxic shock and arthritis in a animal model 2005
Design, synthesis and antiinflammatory activity of novel phthalimide derivative, structurally related to thalidomide 2005
Evaluating the prophylactic potential of the phthalimide derivative LASSBio-552 on allergen-evoked inflammation in rats 2005
Hydrolysis of new phthalimide-derivatives esters catalyzed by immobilized lipase 2005
The molecular basis for coxib inhibition of p38alfa MAP-kinase 2005
Comparative Use of Solvent-free KF-Al2O3 and K2CO3 in acetone in the synthesis of quinoxaline 1,4-dioxide derivatives designed as antimalarial drug candidates 2005
Cysteinyl Leukotriene Receptor Antagonists, Thromboxane synthase Inhibitors and Symbiotic Agents: Useful Strategies to Asthma Treatment 2004
Enzymatic hydrolysis by immobilized lipase applied to a new prototype anti-asthma drug 2004
The therapeutic potential of a new phosphodiesterase inhibitor in acute respiratory distress syndrome 2003
Synthesis and antiinflammatory activity of phthalimide derivatives, designed as new thalidomide analogues 2002
Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists 2002
O renascimento de um fármaco: talidomida 2001
Agentes Antiasmáticos Modernos: Antagonistas de Receptores de Leucotrienos Cisteínicos 2001
Synthesis and analgesic activity of novel N-acilarilhydrazones and isosters, derived from natural safrole 2000
Remarkable fast O-alkylation of phthalimide derivatives, designed as antiasthmatic candidates, under microwave irradiation in dry media 2000
Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole 1999
New antithrombotic aryl-sulfonylthiosemicarbazide derivatives synthesized from natural safrole 1999
Synthesis and antiinflammatory and analgesic activity of novel sulfonylhydrazones derivatives, from natural safrole 1999
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW DERIVATIVES N-ACYLHYDRAZONES CANDIDATES FOR ANTI-LEISHMANIA AGENTS 2017
Pharmacological evaluation of a new series of sulfonamide derivatives in the control of LPS induced lung injury in mice 2014
Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR dual inhibitors 2014
Planejamento, síntese e avaliação farmacológica de compostos análogos inferiores de LASSBio-294 2014
Atividade citotóxica de derivados N-acilidrazônicos análogos a combretastatina A4 2014
Medicinal Chemistry profile of a new trypanomicide prototype LASSBio-1064 2014
ANTIPROLIFERATIVE ACTIVITY OF N-ACYLHYDRAZONE DERIVATIVES DESIGNED AS TUBULIN POLYMERIZATION INHIBITORS 2014
Study of leishmanicidal activity of derivatives from combretastatin A4 2013
Novel Sulfonylhydrazone derivative reduces diabetic neuropathy in streptozotocin-injected rats 2013
Anti-amastigote activity of novel analogues of LASSBio-1064 2013
Relação estrutura-atividade de análogos de LASSBio-1586 2013
Pharmacological Evaluation of a New Series of Sulfonamide Derivatives 2013
Sulfonylhydrazone derivative reduce mechanical allodynia and thermal hyperalgesia 2013
Otimização da atividade citotóxica e avaliação de mutagenicidade de derivados N-acilidrazônicos inibidores de polimerização de beta-tubulina. 2012
Desenho, síntese, efeito citotóxico e antiinflamatório de novos análogos do imatinibe 2012
Avaliação da atividade leishmanicida de complexos de vanádio de LASSBio-1064 2012
Discovery of novel anti-inflammatory drug candidates designed as p38 MAPK inhibitors 2012
Screening of new compounds that inhibit the HIV-1 replication 2011
Síntese e avaliação farmacológica de novas N-fenilsulfonamidas moduladoras da resposta inflamatória pulmonar. 2011
Planejamento, síntese e determinação da atividade citotóxica de novos análogos da combretastatina A4. 2011
Evaluation of antinociceptive and antiinflammatory activities of novel N-acylhydrazone-derivatives designed by molecular simplification at prototype LASSBio-294 2011
Novos Derivados sulfonilidrazônicos com atividade hipoglicemiante no modelo animal de diabetes tipo 1 2010
Screening of new compounds that inhibit the replication of HIV-1 2010
Searching for new drugs to inhibit the neuraminidase activity of influenza viruses 2010
Pre-Clinical Pharmacokinetic study of LASSBio-468: A new achiral thalidomide analogue 2010
Antinociceptove and antiinflammatory activities of novel N-acylhydrazone derivatives designed as piroxicam analogues. 2010
Avaliação da atividade antinociceptiva e antiinflamatória de complexos de zinco dos protótipos LASSBio-466 e LASSBio-1064. 2010
Novos inibidores da protein quinase ativada por mitógeno p38: análogos do protótipo LASSBio-998 2010
Estudios para identificación de nuevos agentes tripanomicidas análogos del protótipo LASSBio-1064 2010
Proposta de modelo farmacofórico para o meclonazepam e outros benzodiazepínicos esquistossomicidas. 2009
Planejamento, síntese e caracterização do perfil antiinflamatório 2009
Identificação de novos ligantes dos receptores ativados por proliferação peroxissomal gamma 2009
Estudos para identificação de novos protótipos semicarbazônicos com atividade tripanomicida. 2009
. LASSBio-998: Novo protótipo anti-inflamatório inibidor da MAPK p-38. 2009
Determinação das propriedades estruturais de LASSBio-468: estudos de difração de raios-X e modelagem molecular. 2009
Efecto de la unión a paládio sobre la actividad in vitro em kinetoplástidos de 2-hidroxifenil-N-acilhidrazonas e hidrazidas. 2009
Pharmacokinetic pre-clinical evaluation of LASSBio-596, a new antiasmatic drug candidate, after oral and intravenous administration to rats 2009
Estudos para a identificação de novos protótipos esquistossomicidas análogos ao clonazepam 2008
Mecanismo de ação vasodilatadora do derivado LASSBio-985 2008
Design, synthesis and pharmacological evaluation of new analgesisc and antipyretic N-phenyl-acetamide sulfonamides 2008
Avaliação da atividade antinociceptiva e antiinflamatória de novos derivados N-acilidrazônicos (NAH) pirazínicos 2008
Design, synthesis and pharmacological evaluation of novel analgesic lead-candidates 2008
?Contractile effects of clonazepam and 3-methylclonazepam in adults Schistosoma mansoni: relation with benzodiazepine receptors and calcium channels?. 2008
Novas N-acilidrazonas pirazínicas antiinflamatórias e analgésicas, desenhadas por otimização do protótipo LASSBio-1018 2008
Novos protótipos quinoxalínicos antiinflamatórios:estudos de docking, síntese e avaliação farmacológica 2007
Modulation of mouse lung inflammatory response by LASSBio-998 2007
Desenvolvimento de derivados N-acilidrazônicos quinoxalínicos como potenciais anti-Chagas 2006
Desenvolvimento de candidatos a fármacos antitrombóticos 2006
Perfil farmacológico de novos derivados N-acilidrazônicos quinoxalínicos 2006
Novos Compostos Candidatos a Inibidores da trans-Sialidase de Trypanossoma cruzi 2005
CoMFA, síntese e avaliação farmacológica de novos AINEs desenhados como inibidores da proteína cinase ativada por mitógeno p-38 2005
Determinação da potência analgésica e do perfil antitrombótico de derivado N-acilidrazônico análogo ao AAS, LASSBio-917. 2005
Síntesis de nuevos derivados de 1,4-di-N-óxido de quinoxalina como agentes antituberculosos 2005
Síntesis y evaluación de la actividad antimalárica de nuevos derivados de 1,4-di-N-óxidos de 2-alquilcarbonil-3-trifluorometilquinoxalina 2005
Nuevos agentes antimaláricos derivados de 1,4-di-N-óxidos-3fenil-quinoxalina-2-carbonitrilo 2005
Síntesis de derivados de 1,4-di-N-óxido de quinoxalina disenados como candidatos a agentes antimaláricos 2005
Síntesis y evaluación biológica de nuevos derivados de 2-furil(tienil)-3-trifluorometil-1,4-di-N-óxidos de quinoxalina 2005
Novel thalidomide analog: LASSBio-542 TNF-alfa and IL-10 inhibitor 2005
Novos análogos do ácido acetil salicílico (AAS), desenhados como candidatos a agentes antiinflamatórios de segunda geração 2004
Planejamento, síntese e avaliação farmacológica de novos derivados 6-bromo-benzodioxola-N-acilidrazônicos, candidatos a protótipos de fármacos analgésicos e antiinflamatórios 2004
Evaluating the prophylactic potential of the phthalimide derivative LASSBio 552 on allergen-evoked inflammation in rats 2004
Nova Metodologia Sintética de Obtenção One-pot de Derivados hidrazínicos e hidrazônicos a partir de Ácidos Carboxílicos 2003
Novos Derivados N-acilidrazônicos do Núcleo Tieno [2',3':4,5]benzo[d][1,3]dioxola, desenhados a partir do Protótipo LASSBio 294 2003
Análogos Amídicos do Sulindaco Sulfona, Desenhados como Candidatos à Novos Antiinflamatórios de Segunda Geração 2003
Monitoração da Publicidade e Propaganda de Medicamentos do Estado do Rio de Janeiro 2003
A novel phenoxi-phthalimid acid derivative LASSBio 552 caused a selective inhibition of allergen-evoked eosinophil recruitment in sensitized rats 2003
Novos análogos da talidomida, desenhados por hibridação molecular como inibidores da enzima PGHs e da modulação do TNF-a. 2002
Novos candidatos a protótipos de fármacos analgésicos, desenhados como agonistas canabinóides. 2002
Bloqueio seletivo do infiltrado eosinofílico alérgico observado após tratamento com o derivado ftalimídico LASSBio 552 em ratos ativamente sensibilizados 2002
A história do Safrol (Piper hispidinervum, Ocotea pretiosa) no LASSBio 2002
Planejamento racional de novos protótipos de agentes antiinflamatórios no LASSBio: histórico e perspectivas 2002
Efeito imunomodulador de protótipos a farmacos antiinflamatórios em modelos de inflamação aguda e crônica 2002
Estudo da atividade de novos candidatos a protótipos de fármacos analgésicos, desenhados como agonistas canabinóides 2002
Synthesis of a new anti-asthmatic drug catalyzed by immobilized lipase 2002
Síntese, Avaliação Farmacológica e Desenvolvimento de Modelo Farmacofórico de Novos Análogos da Talidomida 2001
Planejamento, Síntese e Avaliação Farmacológica de Novos Derivados Ftalimídicos como Candidatos a Antagonistas de Receptores de Leucotrienos 2001
Efeito antiinflamatório de compostos derivados da talidomida na inflamação pulmonar em camundongos induzida por lipopolisacarídeo 2001
Estudo de novos derivados ftalimídicos com potencial atividade antagonista de receptores de leucotrienos cisteínicos em contrações induzidas por LTD4 em traquéias de cobaia 2001
Efeito antiinflamatório de análogos da talidomida após inalação de lipopolisacarídeo por camundongos 2001
Antiinflammatory effect of thalidomide compounds on LPS-induced inflammation in mouse lung 2001
Planejamento, síntese e avaliação farmacológica das propriedades antiinflamatórias de novos derivados ftalimídicos piperazínicos, desenhados por hibridação molecular como inibidores de fosfodiesterases 2000
Planejamento, síntese e avaliação de novos candidatos a protótipos de agentes antiinflamatórios, desenhados como inibidores de PGHS-2 por simplificação molecular 2000
Inhibition of LPS-induced TNF-alfa and neutrophil influx into mouse lung by treatment with new potentially phosphodiesterase inhibitors 2000
Analgesic and antiinflammatory activities of new molecules rationally planned as selective inhibitors of PGHS-2 enzyme 2000
Atividade analgésica e antiinflamatória de derivados benzilideno-6-metil-3,4-metilenodioxi-benzenosulfonilidrazida substituídos 1999
Planejamento e Síntese de Novos Padrões Estruturais de Derivados N-acilidrazônicos, propostos como novos candidatos a agentes antiinflamatórios 1999
Utilização do microondas em reações de O-alquilação de derivados ftalimídicos funcionalizados, planejados como potenciais agentes anti-asmáticos 1999
Síntese diastereosseletiva de novos derivados hidrazônicos, planejados como novos protótipos de agentes antiinflamatórios 1998
Síntese e avaliação farmacológica de novos derivados N-sulfonilarilidrazônicos: analgésicos 1998
Síntese e avaliação farmacológica de novos derivados arilsulfonamídicos, candidatos a antagonistas de receptores de tromboxana: antitrombóticos. 1998
Atividade antiagregante plaquetária de novos derivados análogos à antagonistas de receptores TXA2 1998
Síntese e Avaliação Farmacológica de novas sulfonilidrazonas planejadas racionalmente como agentes antitrombóticos 1997
Atividade antiagregante plaquetária de novos análogos de inibidores duplos TXS e TPant 1997
Síntese de um novo análogo do SQ-29,548, agente antitrombótico, antagonista de receptores de TXA2, a partir do safrol 1996
Estudo conformacional de um composto com perfil antagonista de receptores de TXA2 e inibidor de tromboxana sintase 1996
Antitrombóticos: Desenvolvimento de novos agentes PATant; Tpant; ou de ação dupla: TXSi/TPant 1996
Síntese de um novo análogo do sulotrobano, agente antitrombótico, antagonista de receptores TXA2, a partir do safrol 1995
Modelagem molecular do sulotrobano, um antagonista de receptores TXA2 e de um análogo proposto 1995
Publicações:
Minha Rede: